Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fluorescent dye guides Stomach-Sparing surgery for early cancer

NCT ID NCT07708012

Disease control Sponsor: wangdongsheng Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests a surgical technique for early stomach cancer that combines a camera in the abdomen (laparoscopy) with a flexible tube down the throat (endoscopy). Doctors inject a fluorescent dye near the tumor to highlight the first lymph nodes that might contain cancer. If those nodes are cancer-free, they remove only the tumor and a small part of the stomach, preserving more normal function. The goal is to see if this approach is safe and effective while reducing side effects compared to standard surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a combined laparoscopic and endoscopic surgical procedure using fluorescent dye (indocyanine green) to identify and remove sentinel lymph nodes and the primary tumor
What this could lead to
If successful, this approach could offer a less invasive, stomach-preserving surgical option for early stomach cancer patients, reducing long-term side effects.
What could go wrong
This is a small, single-center study with only 30 participants, so results may not apply broadly. The procedure's safety and effectiveness need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-80, any gender; 2. Gastric adenocarcinoma confirmed by gastroscopic biopsy, with a single lesion; 3. Clinical staging cT1N0M0 based on enhanced CT, endoscopic ultrasound and other imaging evaluations (tumour limited to the mucosa or submucosa with no evidence of lymph node or distant metastasis); 4. Absolute indications for endoscopic submucosal dissection (ESD), with lesions no larger than 5cm, or cases where endoscopic removal is difficult. Absolute indications for ESD (differentiated carcinoma, mucosal T1a stage, without ulcer ≤2 cm or with ulcer ≤3 cm; undifferentiated carcinoma without ulcer ≤2 cm. Difficult cases for endoscopic removal: negative "lifting sign", laterally spreading tumours and scar ulcers etc.); 5. Meets eCURA score criteria for non-curative ESD requiring additional surgery; 6. ECOG performance status 0-1; 7. Patient fully informed and consents, signing the consent form. Note: For inclusion, meeting either criterion ④ or ⑤ is sufficient. Exclusion Criteria: 1. Pregnant or breastfeeding women; 2. Those with a history of major upper abdominal surgery where severe abdominal adhesions are expected; 3. Patients with recurrent gastric cancer, multiple primary tumours, or those who have undergone preoperative chemoradiotherapy; 4. Those meeting ESD indications and having completed curative endoscopic resection according to eCURA standards \[12,13\]; 5. Patients with other unresectable malignant tumours; 6. Those with severe heart, lung, liver, or kidney dysfunction who cannot tolerate general anaesthesia and surgery; 7. Those allergic to indocyanine green (ICG) or nano carbon tracers; 8. Those with mental illness who cannot cooperate with the study and follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early gastric cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma digestive system neoplasm gastric adenocarcinoma gastric neoplasm microinvasive gastric cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early-stage upper gastrointestinal cancer Endoscope Laparoscopy-assisted surgery Stomach cancer, adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Qingdao University Affiliated Hospital West Coast Campus

    Qingdao, Shandong, 266000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.